Skip to main content
Hyundai ADM Bio lnc. logo

Hyundai ADM Bio lnc. — Investor Relations & Filings

Ticker · 187660 ISIN · KR7187660006 KO Professional, scientific and technical activities
Open in API
Filings indexed 251 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 187660

About Hyundai ADM Bio lnc.

http://hdadmbio.com/eng/

Hyundai ADM Bio Inc. is a contract research organization (CRO) that provides comprehensive services for clinical trials. The company's offerings span the full clinical development lifecycle, including regulatory affairs, medical writing, clinical operations, project management, data management, and biostatistics. A primary research focus is in oncology, where the company has developed a novel approach to address drug 'pseudo-resistance'. This strategy involves selectively targeting Cancer-Associated Fibroblasts (CAFs) to enhance the delivery and efficacy of anticancer drugs by improving their access to tumor cells. The company supports various study phases and therapeutic areas, with a specialized emphasis on advancing cancer treatment methodologies.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서 (제25기) 2026.01.01–2026.03.31” and contains detailed company overviews, financial data, share capital changes, business activities, and other substantive disclosures for a quarter. It is clearly an interim/quarterly report, not merely an earnings highlight or publication announcement. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) ((불응성/재발성 고형암 대상 펨브롤리주맙과 PenetriumTM 병용요법 1상 임상시험계획 변경승인 신청))
Regulatory Filings Classification · 75% confidence The document is a Korean stock exchange regulatory disclosure titled “투자판단 관련 주요경영사항(임상시험계획 변경승인신청)” detailing an application for approval of a clinical trial plan change. It is not a financial report (e.g., 10-K, quarterly report), earnings release, dividend notice, proxy statement, or other specific category. It is a general regulatory announcement of a material business event under listing rules, fitting the fallback category “Regulatory Filings (RNS).”
2026-05-13 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a detailed report about a capital increase through a rights offering (유상증자결정) by the company 페니트리움바이오사이언스 주식회사. It includes specifics such as the number and type of new shares, pricing methods, subscription details, allocation methods, and related regulatory references. The document is addressed to the Financial Services Commission and the Korea Exchange, indicating it is a regulatory filing related to capital raising. The content is focused on the decision and details of the capital increase, not a general financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing activity, not just an announcement or summary.
2026-04-30 Korean
증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is titled '증권신고서(지분증권)' which translates to 'Securities Registration Statement (Equity Securities)'. It is addressed to the Financial Services Commission and contains detailed information about the company's securities offering, including the number and type of shares to be issued, investment risks, business risks, financial conditions, and other disclosures relevant to a securities registration. The document includes extensive risk factors, financial data, and investment considerations typical of a prospectus or registration statement filed in connection with a public offering of shares. This type of document is a regulatory filing related to capital raising and securities issuance, not an annual report, earnings release, or other report types. It is not a brief announcement or a certification but a comprehensive disclosure document. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-04-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is titled “주식등의 대량보유상황보고서(일반)” which translates to a large shareholding status report under Korean capital markets law. It details the number of shares held, percentages, reporting dates, legal basis, and contract information for shareholders crossing significant ownership thresholds. This aligns exactly with our definition for Major Shareholding Notification (MRQ).
2026-03-26 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a previously disclosed 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details amendments to contract dates and confidentiality periods. Since this is a specific regulatory disclosure regarding a contract amendment and does not fit into categories like Annual Reports, Earnings Releases, or M&A, it falls under the general regulatory filing category.
2026-03-17 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.